ATRX and central nervous system cancer: In the multinomial logistic regression analysis, after adjusting for gender, age, and WHO grade, the incidence of epilepsy in glioma patients with ATR-X-positive expression was significantly reduced (P = 0.029), and the risk was 56% lower than that in the ATR-X-negative expression group (OR = 0.44; 95% CI: 0.21, 0.92).